References
- Hoofnagle J H, Mullen K D, Jones D B. Treatment of chronic non-A non-B hepatitis with recombinant human alpha interferon. A preliminary report. N Engl J Med 1986; 315: 1575–8
- Di Bisceglie A M, Martin P, Kassianides C. Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N Engl J Med 1989; 321: 1506–10
- Davis G L, Balart L A, Schiff E R. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized controlled trial. N Engl J Med 1989; 321: 1501–6
- Kiyosawa K, Sodeyama T, Nakano Y. Treatment of chronic non-A non-B hepatitis with human interferon β. Antiviral Res 1989; 12: 151–62
- Kuo G, Choo Q-L, Alter H J. An assay for circulating antibodies to a major etiologic virus of human non-A non-B hepatitis. Science 1989; 244: 362–4
- Weiner A J, Kuo G, Bradley D W. Detection of hepatitis C viral sequences in non-A non-B hepatitis. Lancet 1990; 335: 1–3
- Garson J A, Tedder R S, Briggs M. Detection of hepatitis C viral sequences in blood donations by ‘nested’ polymerase chain reaction and prediction of infectivity. Lancet 1990; 335: 1419–22
- Okamoto H, Okada S, Sugiyama Y. Detection of hepatitis C virus RNA by a two-stage polymerase chain reaction with two pairs of primers deduced from the 5′-noncoding region. Jpn J Exp Med 1990; 60: 215–22
- Esteban J I, Esteban R, Viladomiu L. Hepatitis C virus antibodies among risk groups in Spain. Lancet 1989; 2: 294–7
- Van der Poel C L, Reesink H W, Lelie P N. Anti-hepatitis C antibodies and non-A non-B post-transfusion hepatitis in the Netherlands. Lancet 1989; 2: 297–8
- Roggendorf M, Deinhardt F, Rasshofer R. Antibodies to hepatitis C virus. Lancet 1989; 2: 324–5
- Colombo M, Kuo G, Choo Q-L. Prevalence of antibodies to hepatitis C virus in Italian patients with hepatocellular carcinoma. Lancet 1989; 2: 1006–8
- Alter H J, Purcell R H, Shih J W. Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A non-B hepatitis. N Engl J Med 1989; 321: 1494–1500
- Kiyosawa K, Sodeyama T, Tanaka E. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology 1990; 12: 671–5
- Tanaka E, Kiyosawa K, Sodeyama T. Significance of antibody to hepatitis C virus in Japanese patients with viral hepatitis: relationship between anti-HCV antibody and prognosis of non-A non-B post-transfusion hepatitis. J Med Virol 1991; 33: 117–22
- Kiyosawa K, Tanaka E, Sodeyama T. Transition of antibody to hepatitis C virus from chronic hepatitis to hepatocellular carcinoma. Jpn J Cancer Res 1990; 81: 1089–91
- Okamoto H, Okada S, Sugiyama Y. The 5′-terminal sequence of the hepatitis C virus genome. Jpn J Exp Med 1990; 60: 167–77
- Kiyosawa K, Akahane Y, Nagata A, Furuta S. Hepatocellular carcinoma after non-A non-B posttransfusion hepatitis. Am J Gastroenterol 1984; 79: 777–81
- Yousuf M, Nakano Y, Tanaka E, Sodeyama T, Kiyosawa K. Persistence of viremia in patients with type-C chronic hepatitis during long-term follow-up. Scand J Gastroenterol 1992; 27: 812–6
- Mattsson L, Gutierrez R A, Dawson G J, Lesniewski R R, Mushahwar I K, Weiland O. Antibodies to recombinant and synthetic peptides derived from the hepatitis C virus genome in long-term-studied patients with posttransfusion hepatitis C. Scand J Gastroenterol 1991; 26: 1257–62
- Kanai K, Iwata K, Nakao K, Kako M, Okamoto H. Suppression of hepatitis C virus RNA by interferon-α. Lancet 1990; 336: 245
- Farci P, Alter H J, Wong D. A long-term study of hepatitis C virus replication in non-A non-B hepatitis. N Engl J Med 1991; 325: 98–104